Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Deferred Taxes of -$756000.0 for Q2 2023, down 1121.62% year-over-year from $74000.0 in Q2 2022, and down 679.38% quarter-over-quarter from -$97000.0 in Q1 2023.
Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023) Analysis & Trends
Zentalis Pharmaceuticals' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$756000.0 for Q2 2023.
- In Q2 2023, Deferred Taxes fell 1121.62% year-over-year to -$756000.0; the TTM figure through Mar 2024 stood at -$756000.0 (up 4.55% YoY), while the FY2023 annual figure was -$853000.0, down 10.92% from the prior year.
- Deferred Taxes for Q2 2023 stood at -$756000.0, down from -$97000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $74000.0 in Q2 2022, with the low at -$769000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -756,000.00 |
| Mar 31, 2023 | -97,000.00 |
| Dec 31, 2022 | -769,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Mar 31, 2022 | -74,000.00 |